Mr. Bush criticized Canonsburg, Pa.-based Mylan, saying that raising the price of EpiPens “too much too quickly” is “dumb business.”
He asserted the EpiPen pricing controversy only a national issue because it’s a widely used product that underwent major price increases at a time when the public feels like “there’s no more room for the healthcare dollar in the budget,” Mr. Bush said.
Fox Business’ Dagen McDowell agreed with Mr. Bush saying, “They use it as a political issue because it involves children, which definitely plays to people’s hearts.”
More articles on supply chain:
5 reasons insurance claims should include UDIs
Senate committee to examine Mylan’s Medicaid rebates
Sarepta plans to sell $225M of stock to support clinical trials, drug commercialization
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.